AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

15 7 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

28 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

22 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

21 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress

11 6 2021 03:00:00 提供 Nasdaq GlobeNewswire

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

11 6 2021 03:00:00 提供 Nasdaq GlobeNewswire

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

12 5 2021 10:00:00 提供 Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2021 Financial Results

29 4 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021

15 4 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Announces Closing of Oncology Business Sale to Servier

01 4 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Shareholders Approve Sale of Oncology Business to Servier

25 3 2021 16:01:00 提供 Nasdaq GlobeNewswire

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease

18 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

01 3 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

26 2 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

25 2 2021 07:00:02 提供 Nasdaq GlobeNewswire

Agios to Present at March Investor Conferences

23 2 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

11 2 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

26 1 2021 16:01:00 提供 Nasdaq GlobeNewswire

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

17 1 2021 10:00:00 提供 Nasdaq GlobeNewswire

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

11 1 2021 07:00:01 提供 Nasdaq GlobeNewswire